论文部分内容阅读
目的探讨血清γ谷氨酰胺转肽酶(γ-GT)对食管鳞癌患者预后的预测价值。方法回顾性分析83例食管鳞癌患者的临床病理资料,按γ-GT表达高低分为高危组和低危组,采用Kaplan-Meier法及Cox回归分析明确γ-GT与预后的关系。结果高危组和低危组患者的1年生存率分别为75.6%和90.2%,2年生存率分别为56.7%和80.3%,3年生存率分别为43.1%和68.8%,两组患者的远期生存情况差异有统计学意义(P=0.015)。Cox风险比例回归分析显示,年龄≥60岁(P=0.032)、肿瘤分期晚(Ⅲ期,P=0.045)、术后无治疗(P=0.017)和治疗前血清γ-GT水平≥22.5 U/L(P=0.022)均为预后不良的影响因素。结论治疗前血清γ-GT水平或可用于预测食管鳞癌患者的预后。
Objective To investigate the prognostic value of serum gamma-glutamyl transpeptidase (γ-GT) in patients with esophageal squamous cell carcinoma. Methods The clinical and pathological data of 83 patients with esophageal squamous cell carcinoma were retrospectively analyzed. According to the expression of γ-GT, the patients were divided into high-risk group and low-risk group. The relationship between γ-GT and prognosis was analyzed by Kaplan-Meier method and Cox regression analysis. Results The 1-year survival rates of high-risk group and low-risk group were 75.6% and 90.2% respectively, the 2-year survival rates were 56.7% and 80.3% respectively, and the 3-year survival rates were 43.1% and 68.8% respectively. There was significant difference in survival between the two groups (P = 0.015). Cox risk proportional regression analysis showed that the serum levels of γ-GT were higher than or equal to 22.5 U / L after treatment (P = 0.017), age ≥ 60 years (P = 0.032) L (P = 0.022) were the influencing factors of poor prognosis. Conclusion Pretreatment serum γ-GT levels can be used to predict the prognosis of patients with esophageal squamous cell carcinoma.